Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paolo A. Schenardi"'
Autor:
Arianna Pani, Alessandra Romandini, Alice Schianchi, Michele Senatore, Oscar M. Gagliardi, Gianluca Gazzaniga, Stefano Agliardi, Tommaso Conti, Paolo A. Schenardi, Matteo Maggi, Stefano D’Onghia, Valentina Panetta, Silvia Renica, Silvia Nerini Molteni, Chiara Vismara, Daniela Campisi, Michaela Bertuzzi, Simona Giroldi, Laura Zoppini, Mauro Moreno, Marco Merli, Marco Bosio, Massimo Puoti, Francesco Scaglione
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
ObjectiveTo evaluate the mean increase of anti-S IgG antibody titer between the basal, pre-booster level to the titer assessed 14 days after the booster dose of BNT162b2.Patients and MethodsThe RENAISSANCE study is an observational, longitudinal, pro
Externí odkaz:
https://doaj.org/article/d1dcb1ec3ced4e7c8587c2fc289b4566
Autor:
Marco Merli, Valeria Cento, Matteo Corradin, Irene Cuppari, Nicola Ughi, Federica Di Ruscio, Michele Senatore, Daniela Campisi, Alessandra Romandini, Paolo Andrea Schenardi, Roberto Crocchiolo, Marco Bosio, Chiara Vismara, Massimo Puoti, Simona Giroldi, Silvano Rossini, Laura Zoppini, Francesco Scaglione, Mauro Moreno, Oscar Massimiliano Epis, Oscar Matteo Gagliardi, Arianna Pani
Publikováno v:
Mayo Clinic Proceedings. 96:2966-2979
Objective: To evaluate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) IgG antibody production after vaccination with BNT162b2 and the protection from symptomatic breakthrough infections in health care workers. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63698eeda953880d6b82b46d64ab4c91
https://doi.org/10.1016/j.mayocp.2021.08.013
https://doi.org/10.1016/j.mayocp.2021.08.013
Autor:
Paolo Andrea Schenardi, Arianna Pani, Erika Diani, A Nani, E Tratta, Francesco Scaglione, R Roncato, Riccardo Giossi, V A Fittipaldo, Danilo Menichelli, Alessandra Romandini, Daniele Pastori, Alessio Farcomeni
Publikováno v:
Web of Science
Background Antithrombotic treatment, including low molecular weight heparin (LMWH), has been proposed as a potential therapy for Coronavirus disease 2019 (COVID-19), to counteract diffuse intravascular clotting activation. However, it is unclear whet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a9e44724316e08e49e70f198d17a37
https://doi.org/10.1093/eurheartj/ehab724.2931
https://doi.org/10.1093/eurheartj/ehab724.2931
Autor:
Alessandra Romandini, Arianna Pani, Paolo Andrea Schenardi, Giulia Angela Carla Pattarino, Costantino De Giacomo, Francesco Scaglione
Publikováno v:
Antibiotics, Vol 10, Iss 4, p 393 (2021)
Antibiotic resistance is a public health threat of the utmost importance, especially when it comes to children: according to WHO data, infections caused by multidrug resistant bacteria produce 700,000 deaths across all ages, of which around 200,000 a
Externí odkaz:
https://doaj.org/article/12e90d8b91ce4984bbf19affa91c9247